HIV-1 MN NO Fragment

* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).

Online Inquiry

CAT# Product Name M.W Molecular Formula Inquiry
H09040 HIV - 1 MN #2023 1509.7 Inquiry
H09186 HIV - 1 MN #2024 1622.9 Inquiry
H09675 HIV - 1 MN #1933 2053.2 Inquiry
H09695 HIV - 1 MN #2047 2124.4 Inquiry
H09699 HIV - 1 MN #1934 2130.4 Inquiry
H09702 HIV - 1 MN #1961 2136.5 Inquiry
H09703 HIV - 1 MN #2008 2136.5 Inquiry
H09705 HIV - 1 MN #1959 2143.5 Inquiry
H09707 HIV - 1 MN #1932 2153.1 Inquiry
H09709 HIV - 1 MN #1956 2161.6 Inquiry
H09712 HIV - 1 MN #1958 2170.6 Inquiry
H09714 HIV - 1 MN #1957 2171.6 Inquiry
H09716 HIV - 1 MN #2037 2173.3 Inquiry
H09718 HIV - 1 MN #1991 2179.4 Inquiry
H09721 HIV - 1 MN #1962 2187.4 Inquiry
H09723 HIV - 1 MN #1925 2194.4 Inquiry
H09728 HIV - 1 MN #2025 2206.6 Inquiry
H09729 HIV - 1 MN #1931 2207.5 Inquiry
H09733 HIV - 1 MN #1994 2212.3 Inquiry
H09735 HIV - 1 MN #2014 2218.7 Inquiry

HIV-1 MN isolate was taken from a pediatric AIDS patient located in the U.S. in 1984. Since MN strain is the most representative epidemic virus in the American population, scientists studied the infectivity of a series of serum samples from children infected with HIV and MN strain. The initial serum antibody titer analysis showed that MN neutralizing antibody was not related to age, sex, CD4 cell count, p24 antigen level, collection pathway, and CDC symptom grade. This viral strain exhibits the same cytopathic effects on H9 cells as HTLV-IIIB. Also infects human neoplastic CD4+ T cells including H9, CEM, U937, Molt 3, Hela CD4+ cells, and human peripheral blood lymphocytes.

Correlation of neutralizing antibody with clinical status.

HIV-l syncytium-inhibiting antibodies have been recently correlated with better clinical outcome in HIV-l e-infected children. This also supports the concept that the humoral immune response to HIV infection plays an important role in determining the course of disease progression. The MN strain is prevalent in the United States and has been used in these studies to maximize the observed possible neutralization activity. However, if autogenous isolates are used, the expected results cannot be determined. Higher neutralizing antibody titers and their correlation with protection may be obtained, as autologous will allow for higher reactivity of type-specific antibodies. On the other hand, the selection deviation caused by virus isolation hinders the ability of autologous virus isolates to accurately express the virus spectrum in vivo. Therefore, even if autologous separation is used, the results may not be accurately reflected in the body. In addition, when isolating autologous viruses, non-neutralizing or poorly neutralizing isolates can be obtained, whether as viruses that have not yet induced antibodies or as escape mutants. This immune-selective escape mutant has been confirmed in vitro and in vivo.

Conclusion

At present, the research of HIV vaccine is still in the exploratory stage, people do not know how to achieve a successful vaccine, all the clinical research is a “conceptual trial”, which is still far from the real vaccine development. More than 20 years of research, more than 100 clinical trials, have not achieved the expected results, the main reason is that there is no clear understanding of the immune protection mechanism of HIV infection. Therefore, strengthening the basic research of HIV infection and immunization, especially from the vaccine point of view, should be the focus of HIV vaccine research for a long time.

References

  1. Guroff, M. R., Roilides, E., Muldoon, R., Venzon, D., Husson, R., Marshall, D., ... & Pizzo, P. A. (1993). Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. Journal of Infectious Diseases, 167(3), 538-546.
  2. Sengupta, S., & Siliciano, R. F. (2018). Targeting the latent reservoir for HIV-1. Immunity, 48(5), 872-895.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Customer Support & Price Inquiry

Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!

 Figure 1. Chemical structure of pentagastrinPentagastrin, known as peptavlon, is a synthetic pentapeptide that p ...

  st-Ht31, a protein kinase A (PKA)-anchoring inhibitor, greatly induces robust cholesterol or phospholipid effl ...

 Gonadorelin acetate, a synthetic decapeptide with sequence Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, is a gon ...

 Ziconotide (previously called SNX-111), currently marketed under the brand name of Prialt, is the synthetic form ...

 10Panx is a panx 1 mimetic inhibitor that easily and reversibly inhibits panx1 currents. In cells that are diffi ...

Quick Inquiry
×
Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.